Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-05 |
2024-09 |
-0.31 |
N/A |
N/A |
N/A |
2024-08-06 |
2024-06 |
-0.25 |
-0.28 |
-0.03 |
-12.00% |
2024-05-09 |
2024-03 |
-0.29 |
N/A |
N/A |
N/A |
2024-05-09 |
2024-03 |
-0.29 |
-0.32 |
-0.03 |
-10.34% |
2024-02-28 |
2023-12 |
-0.32 |
N/A |
N/A |
N/A |
2024-02-28 |
2023-12 |
-0.32 |
-0.3 |
0.02 |
6.25% |
Date |
Firm |
Action |
From |
To |
2022-12-12 |
Citigroup |
Upgrade |
|
Buy |
2022-10-02 |
Oppenheimer |
Upgrade |
Perform |
Outperform |
2022-03-09 |
Piper Sandler |
Upgrade |
|
Overweight |
2021-06-30 |
Berenberg |
Downgrade |
Buy |
Hold |
2021-06-28 |
Oppenheimer |
Downgrade |
Outperform |
Perform |
2021-02-28 |
Piper Sandler |
Upgrade |
|
Overweight |
Date |
Name |
Relation |
Quantity |
Description |
2023-07-09 |
BRODER SAMUEL |
Director |
8.93K |
Stock Award(Grant) |
2023-07-09 |
CAMBRIAN BIOPHARMA INC |
Beneficial Owner of more than 10% of a Class of Security |
5.24M |
Stock Award(Grant) |
2023-09-10 |
CELEBI JOHN |
Chief Executive Officer |
111.31K |
Purchase |
2023-07-09 |
ENGLISH JESSIE |
Director |
8.93K |
Stock Award(Grant) |
2023-07-09 |
HOLMEN BOB |
Director |
25.60K |
Stock Award(Grant) |
2023-07-09 |
HUMER KRISTIAN |
Director |
8.93K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Newtyn Management, Llc |
1.83M |
2.08M |
6.87% |
2023-06-29 |
Vanguard Group Inc |
573.65K |
653.96K |
2.16% |
2023-06-29 |
Bridgeway Capital Management, Inc. |
112.90K |
128.71K |
0.42% |
2023-06-29 |
Duquesne Family Office Llc |
100.00K |
114.00K |
0.38% |
2023-06-29 |
Geode Capital Management, LLC |
98.01K |
111.73K |
0.37% |
2023-06-29 |
Bank of America Corporation |
90.77K |
103.48K |
0.34% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
441.59K |
503.41K |
1.66% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
112.90K |
128.71K |
0.42% |
2023-06-29 |
Vanguard Extended Market Index Fund |
97.70K |
111.38K |
0.37% |
2023-05-30 |
Fidelity Extended Market Index Fund |
46.19K |
67.44K |
0.17% |
2023-08-30 |
iShares Micro Cap ETF |
32.75K |
32.75K |
0.12% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
17.48K |
25.52K |
0.07% |